Matthew Gline, the CEO of $ROIV, sold 289,774 shares of the company on 04-16-2026 for an estimated $8,449,809. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.7% of their shares of this class of stock. Following this trade, they now own 16,736,116 shares of this class of $ROIV stock.
$ROIV Insider Trading Activity
$ROIV insiders have traded $ROIV stock on the open market 71 times in the past 6 months. Of those trades, 0 have been purchases and 71 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:
- VIVEK RAMASWAMY has made 0 purchases and 6 sales selling 4,958,348 shares for an estimated $105,881,463.
- KEITH S MANCHESTER has made 0 purchases and 14 sales selling 4,220,398 shares for an estimated $98,028,231.
- FINANCIAL LP QVT has made 0 purchases and 14 sales selling 4,220,398 shares for an estimated $98,028,231.
- DANIEL ALLEN GOLD has made 0 purchases and 14 sales selling 4,220,398 shares for an estimated $98,028,231.
- FRANK TORTI (President and Vant Chair) has made 0 purchases and 3 sales selling 3,000,000 shares for an estimated $82,039,460.
- MATTHEW GLINE (CEO) has made 0 purchases and 4 sales selling 2,029,774 shares for an estimated $46,173,009.
- MAYUKH SUKHATME (President & CIO) has made 0 purchases and 4 sales selling 1,697,140 shares for an estimated $38,507,031.
- ERIC VENKER (President & Immunovant CEO) has made 0 purchases and 7 sales selling 1,275,000 shares for an estimated $29,723,750.
- RICHARD PULIK (CFO) has made 0 purchases and 2 sales selling 406,731 shares for an estimated $9,122,307.
- MEGHAN FITZGERALD sold 70,000 shares for an estimated $1,921,500
- MELISSA B, EPPERLY sold 41,861 shares for an estimated $1,200,573
- JENNIFER HUMES (Chief Accounting Officer) sold 13,538 shares for an estimated $384,073
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ROIV Hedge Fund Activity
We have seen 247 institutional investors add shares of $ROIV stock to their portfolio, and 137 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SB INVESTMENT ADVISERS (UK) LTD removed 23,901,524 shares (-59.3%) from their portfolio in Q4 2025, for an estimated $518,663,070
- VIKING GLOBAL INVESTORS LP removed 17,151,640 shares (-72.7%) from their portfolio in Q4 2025, for an estimated $372,190,588
- UBS GROUP AG added 15,645,836 shares (+570.0%) to their portfolio in Q4 2025, for an estimated $339,514,641
- MORGAN STANLEY added 14,036,696 shares (+31.7%) to their portfolio in Q4 2025, for an estimated $304,596,303
- RUBRIC CAPITAL MANAGEMENT LP removed 11,000,000 shares (-55.0%) from their portfolio in Q4 2025, for an estimated $238,700,000
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 6,409,859 shares (-75.5%) from their portfolio in Q4 2025, for an estimated $139,093,940
- FMR LLC added 5,012,480 shares (+8.2%) to their portfolio in Q4 2025, for an estimated $108,770,816
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ROIV Congressional Stock Trading
Members of Congress have traded $ROIV stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ROIV Analyst Ratings
Wall Street analysts have issued reports on $ROIV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 02/10/2026
To track analyst ratings and price targets for $ROIV, check out Quiver Quantitative's $ROIV forecast page.
$ROIV Price Targets
Multiple analysts have issued price targets for $ROIV recently. We have seen 6 analysts offer price targets for $ROIV in the last 6 months, with a median target of $33.5.
Here are some recent targets:
- Yasmeen Rahimi from Piper Sandler set a target price of $40.0 on 04/16/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $34.0 on 03/04/2026
- Samantha Semenkow from Citigroup set a target price of $35.0 on 02/10/2026
- Yatin Suneja from Guggenheim set a target price of $30.0 on 02/09/2026
- Corinne Jenkins from Goldman Sachs set a target price of $33.0 on 12/15/2025
- David Risinger from Leerink Partners set a target price of $32.0 on 12/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
